Jefferies Downgrades Eli Lilly to "Underperform" (LLY)

Jefferies Downgrades Eli Lilly to “Underperform” (LLY)


Analysts at Jefferies downgraded pharmaceutical company Eli Lilly & Co. (LLY) early on Friday, due to disappointment in the research and development in its product pipeline.

The analysts downgraded LLY from “Hold” to “Underperform” and now see shares reaching $40, down from the previous target of $49. This new price target suggests a 19% downside to the stock’s Thursday closing price of $49.15.

“We have downgraded Eli Lilly to Underperform from Hold following further R&D disappointment in its pipeline (ramucirumab in breast cancer) as well as the increased strain this will put on future cash flow allocation required to maintain the dividend,” analyst Jeffrey Holford commented. “We see Eli Lilly as one of the strongest bond proxies in the group and see likely pressure on valuation once tapering likely increases in visibility over the next 12 months. Eli Lilly is now our least preferred US stock.”

Eli Lilly shares were down 60 cents, or 1.22%, during pre-market trading on Friday. The stock is down 0.34% year-to-date.

The Bottom Line

Shares of Eli Lilly (LLY) offer a dividend yield of 3.99% based on Thursday’s closing price of $49.15 and the company’s annualized dividend payout of $1.96 per share.

Eli Lilly & Co. (LLY) is not recommended at this time, holding a DARS™ Rating of 3.4 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.

Free Updates

Join over 100,000 investors who get the latest news from

Best Dividend Stocks

Looking for stocks that are poised for growth and pay solid dividends? Visit our list of the:

Best Dividend Stocks

Partner Center

Best CD Rates

Sitting on some extra cash and looking for the most current and profitable CD Rates?

Get The Best CD Rates

14 Day Free Trial

Earn more from your dividend portfolio within the next 14 days.

Sign Up Today